Cann Global Limited (ASX:CGB) Rights Issue Update
Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.
Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.
Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach(R) in key overseas markets.
Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
The Board of Cann Global Limited (ASX:CGB) wishes to update our shareholders on the operations of its 55% owned subsidiary Cann Global Asia Pty Ltd, and its activities in Laos PDR.
On 30 April 2020, Cann Global Ltd (ASX:CGB) lodged the Company's quarterly activities and cashflow reports for the period ended 31 March 2020. This amendment includes an updated cashflow report.
In October 2019, Austrade published a report on Australia's food innovators which Cann Global Limited (ASX:CGB), through its subsidiaries T12 and HHC, is very excited to be a part of.
The South African group, Labat Africa Ltd (JSE:LAB) which announced last year it was entering the medical CANNABIS market, is gaining the interest of High net worth and institutional investors in London and New York.